Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Core Insights - Lyell Immunopharma, Inc. is advancing a pipeline of next-generation CAR T-cell therapies targeting solid tumors and hematologic malignancies [1][3] - The company announced the presentation of initial clinical data for IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for large B-cell lymphoma, at the upcoming ASH Annual Meeting [1][2] Company Overview - Lyell is a clinical-stage company focused on developing CAR T-cell therapies enhanced with technology to generate T cells that resist exhaustion and maintain durable stemness [3] - The company is headquartered in South San Francisco, California, with additional facilities in Seattle and Bothell, Washington [3] Clinical Development - IMPT-314 has received Fast Track Designation from the U.S. FDA for treating relapsed/refractory aggressive B-cell lymphoma [2] - The presentation of IMPT-314's results will occur on December 9, 2024, at the San Diego Convention Center during the ASH Annual Meeting [2]